Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Takeda Pharmaceutical Co Ltd Announces Agreement with Taisho for Distribution of Products of Biofermin; Transfers of a Part of Shares of Biofermin to Taisho


Wednesday, 31 Jul 2013 02:00am EDT 

Takeda Pharmaceutical Co Ltd announced that Takeda and Taisho Pharmaceutical Co., Ltd. (Taisho) have agreed that Takeda will conduct domestic transactions in relation to the sale of the products manufactured by Biofermin Pharmaceutical(Biofermin Pharmaceutical) based on the distributorship granted to Takeda by Taisho for a certain period of time, and also have agreed on the basic terms of such transactions (the "Sale Arrangement”). Sale Arrangement has been agreed upon following the execution of the agreement between Taisho and Biofermin Pharmaceutical for an exclusive distributorship agreement for products manufactured by Biofermin Pharmaceutical. In addition to the Sale Arrangement, Takeda has also agreed with Taisho on the transfer of approximately 8.15% voting rights (972,320 shares) of Biofermin Pharmaceutical to Taisho.